by Lisa Nadal | Feb 21, 2024 | 2024, Press Releases
More detailsby Lisa Nadal | Feb 20, 2024 | 2024, Press Releases
FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft Tissue Sarcoma An Independent Data and Safety...by Lisa Nadal | Jul 4, 2023 | Press Releases
The study was conducted by scientists at Philochem AG, the wholly owned Swiss subsidiary company of the Philogen group. The paper can be accessed on the Nature Chemistry website at the following link. Nat_chem_280223_press_releaseby last | Nov 13, 2022 | 2020, Press Releases
Philochem will be attending the 10th World ADC Conference in London (United Kingdom) from March 2 to 5, 2020 10th World ADC London Dr. Samuele Cazzamalli will give a plenary lecture on: “Small Molecule-DrugConjugates: Getting small to enhance targeting” Jacopo Millul...by Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors. The...by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific
The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...
Recent Comments